Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Completed

Looking for future studies?

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

20 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of Parkinson's disease
Stage 2 - Stage 4 of revised Hoehn & Yahr severity score
Taking L-dopa/DCI without changing dose and regimen
Having motor complication
Other inclusion criteria as specified in the study protocol

Exclusion criteria

Previous participation in ONO-2506PO or ONO-2506 protocol
Previous brain surgery for Parkinson's disease
Presence or history of serious cardiac disease
Other exclusion criteria as specified in the study protocol

Treatment and study plan

ONO-2506PO

Drug

Primary outcomes

Unified Parkinson's disease rating scale (Part III)

Secondary outcomes

Unified Parkinson's disease rating scale (Part I, II, IV and total), revised Hoehn & Yahr severity score and off time

Sponsors and collaborators

Lead sponsor

Ono Pharmaceutical Co., Ltd.

Industry

Registry information

Important dates

Study start: 2004
Primary completion: 2005
First posted: Sep 21, 2005
Registry last updated: Oct 11, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed